Halozyme Therapeutics, Inc. (HALO) Given Consensus Recommendation of “Hold” by Brokerages
Halozyme Therapeutics, Inc. (NASDAQ:HALO) has been given a consensus rating of “Hold” by the ten research firms that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $16.67.
A number of research firms have commented on HALO. Piper Jaffray Companies set a $20.00 price target on Halozyme Therapeutics and gave the company a “buy” rating in a research report on Thursday, August 10th. Barclays PLC reiterated an “overweight” rating and issued a $16.00 price target on shares of Halozyme Therapeutics in a research report on Friday, June 23rd. Zacks Investment Research upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a research report on Friday, August 25th. BidaskClub lowered Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, July 1st. Finally, Jefferies Group LLC reiterated an “underperform” rating and issued a $7.00 price target (up previously from $6.75) on shares of Halozyme Therapeutics in a research report on Thursday, August 10th.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/11/halozyme-therapeutics-inc-halo-given-consensus-recommendation-of-hold-by-brokerages.html.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in HALO. Ameritas Investment Partners Inc. bought a new stake in shares of Halozyme Therapeutics in the 1st quarter valued at about $122,000. Teacher Retirement System of Texas acquired a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at about $129,000. Arrowstreet Capital Limited Partnership acquired a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at about $131,000. Prudential Financial Inc. lifted its stake in shares of Halozyme Therapeutics by 8.7% in the 2nd quarter. Prudential Financial Inc. now owns 11,726 shares of the biopharmaceutical company’s stock valued at $150,000 after purchasing an additional 940 shares during the period. Finally, Dynamic Technology Lab Private Ltd acquired a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at about $171,000. Hedge funds and other institutional investors own 85.06% of the company’s stock.
Shares of Halozyme Therapeutics (NASDAQ:HALO) traded up 1.06% during trading on Wednesday, hitting $17.09. The stock had a trading volume of 1,008,429 shares. The stock’s market capitalization is $2.29 billion. Halozyme Therapeutics has a one year low of $8.18 and a one year high of $17.75. The stock has a 50 day moving average price of $15.04 and a 200-day moving average price of $13.66.
Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.02. The firm had revenue of $33.80 million for the quarter, compared to the consensus estimate of $31.76 million. The company’s revenue was up 1.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.21) EPS. On average, equities research analysts predict that Halozyme Therapeutics will post ($0.13) earnings per share for the current year.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.
Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.